{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:33:18Z","timestamp":1775802798941,"version":"3.50.1"},"reference-count":43,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2024,2,11]]},"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Ongoing controversy exists regarding optimal management of disease modifying therapy (DMT) in older people with multiple sclerosis (pwMS). There is concern that the lower relapse rate, combined with a higher risk of DMT-related infections and side effects, may alter the risk-benefit balance in older pwMS. Given the lack of pwMS above age 60 in randomised controlled trials, the comparative efficacy of high-efficacy DMTs such as ocrelizumab has not been shown in older pwMS. We aimed to evaluate the comparative effectiveness of ocrelizumab, a high-efficacy DMT, versus interferon\/glatiramer acetate (IFN\/GA) in pwMS over the age of 60.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using data from MSBase registry, this multicentre cohort study included pwMS above 60 who switched to or started on ocrelizumab or IFN\/GA. We analysed relapse and disability outcomes after balancing covariates using an inverse probability treatment weighting (IPTW) method. Propensity scores were obtained based on age, country, disease duration, sex, baseline Expanded Disability Status Scale, prior relapses (all-time, 12 months and 24 months) and prior DMT exposure (overall number and high-efficacy DMTs). After weighting, all covariates were balanced. Primary outcomes were time to first relapse and annualised relapse rate (ARR). Secondary outcomes were 6-month confirmed disability progression (CDP) and confirmed disability improvement (CDI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 248 participants received ocrelizumab, while 427 received IFN\/GA. The IPTW-weighted ARR for ocrelizumab was 0.01 and 0.08 for IFN\/GA. The IPTW-weighted ARR ratio was 0.15 (95% CI 0.06 to 0.33, p&lt;0.001) for ocrelizumab compared with IFN\/GA. On IPTW-weighted Cox regression models, HR for time to first relapse was 0.13 (95% CI 0.05 to 0.26, p&lt;0.001). The hazard of first relapse was significantly reduced in ocrelizumab users after 5 months compared with IFN\/GA users. However, the two groups did not differ in CDP or CDI over 3.57 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In older pwMS, ocrelizumab effectively reduced relapses compared with IFN\/GA. Overall relapse activity was low. This study adds valuable real-world data for informed DMT decision making with older pwMS. Our study also confirms that there is a treatment benefit in older people with MS, given the existence of a clear differential treatment effect between ocrelizumab and IFN\/GA in the over 60 age group.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2023-332883","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T18:22:54Z","timestamp":1709835774000},"page":"767-774","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Comparing ocrelizumab to interferon\/glatiramer acetate in people with multiple sclerosis over age 60"],"prefix":"10.1136","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6447-078X","authenticated-orcid":false,"given":"Yi Chao","family":"Foong","sequence":"first","affiliation":[]},{"given":"Daniel","family":"Merlo","sequence":"additional","affiliation":[]},{"given":"Melissa","family":"Gresle","sequence":"additional","affiliation":[]},{"given":"Katherine","family":"Buzzard","sequence":"additional","affiliation":[]},{"given":"Michael","family":"Zhong","sequence":"additional","affiliation":[]},{"given":"Wei Zhen","family":"Yeh","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3942-4340","authenticated-orcid":false,"given":"Vilija","family":"Jokubaitis","sequence":"additional","affiliation":[]},{"given":"Mastura","family":"Monif","sequence":"additional","affiliation":[]},{"given":"Olga","family":"Skibina","sequence":"additional","affiliation":[]},{"given":"Serkan","family":"Ozakbas,","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6923-0846","authenticated-orcid":false,"given":"Francesco","family":"Patti","sequence":"additional","affiliation":[]},{"given":"Pierre","family":"Grammond","sequence":"additional","affiliation":[]},{"given":"Maria Pia","family":"Amato","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3778-1376","authenticated-orcid":false,"given":"Tomas","family":"Kalincik","sequence":"additional","affiliation":[]},{"given":"Dana","family":"Horakova","sequence":"additional","affiliation":[]},{"given":"Eva","family":"Kubala Havrdova","sequence":"additional","affiliation":[]},{"given":"Bianca","family":"Weinstock-Guttman","sequence":"additional","affiliation":[]},{"given":"Jeanette","family":"Lechner Scott","sequence":"additional","affiliation":[]},{"given":"Cavit","family":"Boz","sequence":"additional","affiliation":[]},{"given":"Maria Jose","family":"Sa","sequence":"additional","affiliation":[]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4278-7003","authenticated-orcid":false,"given":"Anneke","family":"van der Walt","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3951-7501","authenticated-orcid":false,"given":"Chao","family":"Zhu","sequence":"additional","affiliation":[]}],"member":"239","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"2024112820003315000_95.8.767.1","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1177\/1352458519866613","article-title":"Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis","volume":"26","author":"Schwehr","year":"2020","journal-title":"Mult Scler"},{"key":"2024112820003315000_95.8.767.2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516634871"},{"key":"2024112820003315000_95.8.767.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70256-X"},{"key":"2024112820003315000_95.8.767.4","doi-asserted-by":"publisher","DOI":"10.1007\/S11910-020-01079-7"},{"key":"2024112820003315000_95.8.767.5","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/WCO.0000000000000701","article-title":"Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis","volume":"32","author":"Schweitzer","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"2024112820003315000_95.8.767.6","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520964778"},{"key":"2024112820003315000_95.8.767.7","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.799138","article-title":"Evolution of disease modifying therapy benefits and risks: an argument for de-escalation as a treatment paradigm for patients with multiple sclerosis","volume":"12","author":"Vollmer","year":"2022","journal-title":"Front Neurol"},{"key":"2024112820003315000_95.8.767.8","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1177\/1352458518765656","article-title":"Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60","volume":"25","author":"Hua","year":"2019","journal-title":"Mult Scler"},{"key":"2024112820003315000_95.8.767.9","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.msard.2019.02.028","article-title":"Changes in patient-reported outcomes between continuers and discontinuers of disease modifying therapy in patients with multiple sclerosis over age 60","volume":"30","author":"Hua","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"2024112820003315000_95.8.767.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30475-6"},{"key":"2024112820003315000_95.8.767.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"2024112820003315000_95.8.767.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014656"},{"key":"2024112820003315000_95.8.767.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09248-6"},{"key":"2024112820003315000_95.8.767.14","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamaneurol.2023.1625","article-title":"Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis","volume":"80","author":"Roos","year":"2023","journal-title":"JAMA Neurol"},{"key":"2024112820003315000_95.8.767.15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010376"},{"key":"2024112820003315000_95.8.767.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468"},{"key":"2024112820003315000_95.8.767.17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jamaneurol.2014.4147","article-title":"Comparison of switch to fingolimod or interferon beta\/glatiramer acetate in active multiple sclerosis","volume":"72","author":"He","year":"2015","journal-title":"JAMA Neurol"},{"key":"2024112820003315000_95.8.767.18","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B"},{"key":"2024112820003315000_95.8.767.19","doi-asserted-by":"publisher","DOI":"10.1177\/1352458506070775"},{"key":"2024112820003315000_95.8.767.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1206328"},{"key":"2024112820003315000_95.8.767.21","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s00415-016-8182-4","article-title":"Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon Beta-1A in patients with relapsing-remitting multiple sclerosis","volume":"263","author":"Newsome","year":"2016","journal-title":"J Neurol"},{"key":"2024112820003315000_95.8.767.22","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-330104"},{"key":"2024112820003315000_95.8.767.23","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamaneurol.2023.1542","article-title":"Comparison between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation","volume":"80","author":"Zhu","year":"2023","journal-title":"JAMA Neurol"},{"key":"2024112820003315000_95.8.767.24","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1177\/09622802211047345","article-title":"G-computation and doubly robust standardisation for continuous-time data: a comparison with inverse probability weighting","volume":"31","author":"Chatton","year":"2022","journal-title":"Stat Methods Med Res"},{"key":"2024112820003315000_95.8.767.25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jspi.2004.06.060","article-title":"Why prefer double robust estimators in causal inference","volume":"129","author":"Neugebauer","year":"2005","journal-title":"J Statist Plann Inference"},{"key":"2024112820003315000_95.8.767.26","doi-asserted-by":"publisher","DOI":"10.1177\/0962280210386207"},{"key":"2024112820003315000_95.8.767.27","article-title":"A practical guide for using propensity score weighting in R","volume":"20","author":"Olmos","year":"2015","journal-title":"Pract Assess Res Eval"},{"key":"2024112820003315000_95.8.767.28","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6607"},{"key":"2024112820003315000_95.8.767.29","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3697"},{"key":"2024112820003315000_95.8.767.30","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(23)00154-0"},{"key":"2024112820003315000_95.8.767.31","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ene.13181","article-title":"Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis","volume":"24","author":"Bonenfant","year":"2017","journal-title":"Eur J Neurol"},{"key":"2024112820003315000_95.8.767.32","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-313760"},{"key":"2024112820003315000_95.8.767.33","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10029-9"},{"key":"2024112820003315000_95.8.767.34","first-page":"1","article-title":"Prespecified subgroup analyses of ocrelizumab efficacy in patients with primary progressive multiple sclerosis from the phase III ORATORIO study","volume":"20","author":"Wolinsky","year":"2018","journal-title":"Int J MS Care"},{"key":"2024112820003315000_95.8.767.35","doi-asserted-by":"crossref","first-page":"103171","DOI":"10.1016\/j.msard.2021.103171","article-title":"Evaluation of ocrelizumab in older progressive multiple sclerosis patients","volume":"55","author":"Epstein","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"2024112820003315000_95.8.767.36","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2003.010090"},{"key":"2024112820003315000_95.8.767.37","doi-asserted-by":"crossref","first-page":"103086","DOI":"10.1016\/j.msard.2021.103086","article-title":"Review of phase III clinical trials outcomes in patients with secondary progressive multiple sclerosis","volume":"54","author":"McAdams","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"2024112820003315000_95.8.767.38","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30069-3"},{"key":"2024112820003315000_95.8.767.39","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.37"},{"key":"2024112820003315000_95.8.767.40","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181d6b125"},{"key":"2024112820003315000_95.8.767.41","doi-asserted-by":"crossref","first-page":"e1316","DOI":"10.1212\/WNL.0000000000005302","article-title":"Psychiatric comorbidity is associated with disability progression in multiple sclerosis","volume":"90","author":"McKay","year":"2018","journal-title":"Neurology"},{"key":"2024112820003315000_95.8.767.42","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1212\/WNL.0000000000004885","article-title":"Effects of physical comorbidities on disability progression in multiple sclerosis","volume":"90","author":"Zhang","year":"2018","journal-title":"Neurology"},{"key":"2024112820003315000_95.8.767.43","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1080\/14740338.2020.1807002","article-title":"Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review","volume":"19","author":"Ng","year":"2020","journal-title":"Expert Opin Drug Saf"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2023-332883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T04:02:18Z","timestamp":1732852938000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2023-332883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":43,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,7,15]]},"published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1136\/jnnp-2023-332883"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2023-332883","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]}}}